SAN DIEGO – Sept. 24, 2018 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the U.S. commercial launch of three new biologics offerings to include traditional bone allograft, amniotic membrane DS and additional form factors to the current PropelTM DBM product line. This portfolio expansion demonstrates the Company’s strategic efforts to deliver the most differentiated biologics portfolio in the spine industry.
NuVasive’s newest biologic product lines help promote enhanced clinical outcomes for patients, improved economic outcomes for hospital systems, as well as meet the variety of handling preferences of spine surgeons:
- Traditional Bone Allograft includes cancellous chips, demineralized cancellous chips, cortical cancellous chips and cancellous crushed, which all function as economical bone graft options. Traditional Bone Allograft has osteoconductive properties that provide a scaffold for bone growth, and can be packed into bony voids or gaps in a patient’s skeletal system. This product is available in a variety of grind sizes and volumes.
- Amniotic Membrane DS is a double-sided layer of human amniotic membrane intended to be a biologic barrier that may help prevent adhesions and reduce scar tissue formation near adjacent muscle, nerve and fascia layer The strong, pliable properties of this biologic help it adapt to the surrounding anatomy making it easy to handle and position into place. Amniotic Membrane DS is naturally rich in growth factors and has been shown to control inflammation and reduce bacterial and viral activity at the surgical site, supporting the patient’s overall healing process.
- Propel DBM product line, launched in 2017, now introduces gel, gel plus and putty plus as additional form factors with enhanced handling properties to address surgeon preferences. The gel form factor is packaged in a syringe for convenient graft delivery, while Propel DBM putty plus and gel plus contain cancellous chips for additional osteoconductive properties helping promote bone growth. With a variety of DBM form factors available, surgeons can tailor the graft selection to the clinical needs of the patient.
“The addition of these three new product lines strengthens our comprehensive spine portfolio and further positions NuVasive as a full-service provider of biologics,” said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive. “NuVasive is committed to investing in innovative offerings to meet the clinical and economic needs of our patients, surgeons and hospital partners.”
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Investor & Media Contact: